Evidence map›Paper›PMID 33490865›Full record

ArticleJNCI cancer spectrum2020

Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome.

Farzana L Walcott, Ping-Yuan Wang, Christine M Bryla, Rebecca D Huffstutler, Neha Singh, Michael N Pollak, Payal P Khincha, Sharon A Savage, Phuong L Mai, Kevin W Dodd and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Farzana L WalcottCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Ping-Yuan WangCardiovascular Branch, National Heart Lung Blood Institute, Bethesda, MD, USA.
Christine M BrylaCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Rebecca D HuffstutlerCardiovascular Branch, National Heart Lung Blood Institute, Bethesda, MD, USA.
Neha SinghGeorge Washington Medical School, Washington, DC, USA.
Michael N PollakMcGill University, Montreal, QC, Canada.
Payal P KhinchaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Sharon A SavageDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-6006-0740
Phuong L MaiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-7486-4974
Kevin W DoddDivision of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Paul M HwangCardiovascular Branch, National Heart Lung Blood Institute, Bethesda, MD, USA.ORCID 0000-0002-5976-7834
Antonio T FojoCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Christina M AnnunziataCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
National Cancer Institute · USNational Heart Lung and Blood Institute · USMcGill University · CAUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLi-Fraumeni syndrome (LFS) is a highly penetrant autosomal dominant cancer predisposition disorder caused by germline

methodsThis study assessed safety and tolerability of metformin in nondiabetic LFS patients and measured changes in metabolic profiles. Adult patients with LFS and germline

resultsWe enrolled 26 participants: 20 females and 6 males. The most common adverse events were diarrhea (50.0%) and nausea (46.2%). Lactic acidosis did not occur, and there were no changes in fasting glucose. Cumulative mean

conclusionsMetformin was safe and tolerable in patients with LFS. It suppressed hepatic mitochondrial function as expected in these individuals. This study adds to the rationale for development of a pharmacologic risk-reduction clinical trial of metformin in LFS.

Identifiers

PMID33490865
PMCPMC7746650
OpenAlexW3042990191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.